Results 161 to 170 of about 7,365,306 (254)
Gut microbial utilization of the alternative sweetener, D-allulose, via AlsE. [PDF]
Commun BiolMinabou Ndjite G +5 more
europepmc +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source
501. [V. 1. a. ð.] "Russian Peasant" Multiplication in Roman Numerals [PDF]
, 1917 Gregory Bryan
openalex +1 more source
Investigation of Optimal Parameters Setting for Negative Pressure Wound Therapy With Instillation and Dwell Time for Hard-To-Heal Wounds With Necrotic Tissue. [PDF]
Int Wound JOhura N +3 more
europepmc +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Erratum to: Training non-native speech contrasts in adults: Acquisition of the English /ð/-/θ/ contrast by francophone [PDF]
, 1987 Donald G. Jamieson, David E. Morosan
openalex +1 more source
Weak D phenotype in transfusion medicine and obstetrics: Challenges and opportunities. [PDF]
World J Exp MedSainath PB, Ramaiyan V.
europepmc +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source